Enforcement Report - Week of July 10, 2024
Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine
A new chapter for Medisca: Sanjay D. Goorachurn appointed as Chief Executive Officer
Medisca Opens MAZ® Lab in Arizona: An Innovation and Customer Resource Center
Medisca Takes Steps to Protect its Innovative Technologies
MONTREAL--(BUSINESS WIRE)--In 2018, Medisca, a global leader in pharmaceutical compounding and personalized medicine, partnered with the Université Laval Faculty of Medicine located in Quebec, Canada. The commitment included funding the establishment of a Chair in Educational Leadership in Chronic Pain Treatment, donating $500,000 to the initiative. Five years later, Medisca is a proud founding partner of the collaborative success of the Université Laval’s Chair in Educational Leadership in Chronic Pain Treatment-Medisca, Dr. Anne Marie Pinard, MD FRCPC, M.(Ed.), and the Quebec Pain Research Network.
Medisca Expands Strategic Partnerships to Drive Patient Access to Critical Medications
PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca, a global company offering pharmaceutical compounding products and services, mixing technology, manufacturing, education services and more, announces plans to lease a standalone 60,000 square foot building to consolidate repackaging and distribution operations in Plattsburgh, NY under one roof.
MONTREAL--(BUSINESS WIRE)--After three successful decades of redefining, shaping, and informing the pharmaceutical compounding industry standard, Medisca is proud to unveil a new global brand identity and corporate positioning that reflects a journey of growth, diversification, and opportunity. Founded in 1989 as a small business with a handful of employees, Medisca has expanded into a global corporation with strategic partners in education, manufacturing, supply chain, and analytical testing that deliver customized solutions with an unwavering commitment to quality and innovation.
MONTREAL--(BUSINESS WIRE)--On May 31, 2022, Medisca, a global supplier of pharmaceutical compounding products, acquired DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.